Lenvaxen-Lenvatinib (4/10)mg

Lenvatinib Description

Lenvaxen-Lenvatinib is a thyroid cancer treatment medication. Lenvatinib is used to treat certain types of thyroid cancer, which have spread to other parts of the body or that can not be treated with radioactive iodine. It is also used to treat certain types of renal cell carcinoma. Renal cell carcinoma is a type of kidney cancer, for renal cell carcinoma treatment lenvatinib is used along with pembrolizumab and everolimus. This combination is used in patients who have received treatment before. Lenvatinib also can be used to treat hepatocellular carcinoma.

Lenvaxen-Lenvatinib Indications

Lenvatinib is in a class of medications called tyrosine kinase inhibitors. It is indicated for the treatment of metastatic thyroid cancer, which has been spread to other parts of the body. It is also used to treat renal cell carcinoma. Renal cell carcinoma is familiar as kidney cancer.

Lenvatinib is used in patients with renal cell carcinoma, who have been treated before with surgery or with chemotherapy. It is also used to treat hepatocellular carcinoma. Hepatocellular carcinoma is a liver cancerous state, which is considered as metastatic liver cancer.

Lenvatinib is used to treat patients with HCC, who have received other treatments before. It is also used to treat endometrial carcinoma.

Lenvaxen-Lenvatinib Mechanism of Action

Lenvatinib is a receptor tyrosine kinase inhibitor. That works by blocking the production and multiplication of cancer cells. It also inhibits the vascular growth factor (VEGFR). VEGFR helps in cancer cell multiplication. By following this process lenvatinib helps in the development of cancer patients and makes them cure.

Dosage and Administration of Lenvaxen-Lenvatinib

Lenvatinib comes in the form of a tablet. It can be taken orally with food. For the treatment of differentiated thyroid cancer, 24mg of lenvatinib is taken daily. To treat renal cell carcinoma (RCC), the recommended dose is 20mg of lenvatinb and 200 mg of pembrolizumab. This combination is used for the first-line treatment. The combination of 18mg of lenvatinib and 5mg of everolimus is used to treat previously treated RCC.
To treat hepatocellular carcinoma (HCC), the recommended dose of lenvatinib is 12 mg for patients equal to 60kg and 8 mg for patients less than 60kg.

Side Effects of Lenvatinib

The common side effects of taking lenvatinib are

• fatigue or tiredness
• rash, redness, itching, or peeling of skin on palms and sole(s) of the feet
• diarrhea
• nausea
• decreased appetite
• weight loss
• headache
• joint and muscle pain
• fever
• burning during urination

The side effects of consuming lenvatinib are not similar for everyone. It can vary from patient to patient. Some of the patients can have serious side effects because of their poor immune system and previous medical conditions.

see our other products: lenvanix 4/10mg, Caboxen 20/80mg, Cabzanix 20mg, Axinix 5mg, Rizonib 250mg, Sotoxen 120mg

for more references read this

A few FAQs About Lenvanex-Lenvatinib